Atomoxetine to Treat Korean Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00568685 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

153

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

DRUG: Atomoxetine Hydrochloride
DRUG: Atomoxetine hydrochloride
DRUG: Atomoxetine hydrochloride

Sponsor

Eli Lilly and Company